Clinical Trials
5
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Cross-Linked Polyelectrolyte (CLP)
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Sorbent Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT02079233
Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Basic Science: Safety, Tolerability, Efficacy of CLP
- Interventions
- Drug: Cross-Linked Polyelectrolyte (CLP)
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Sorbent Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT01944007
- Locations
- 🇺🇸
Jasper Clinic, Inc., Kalamazoo, Michigan, United States
Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Sorbent Therapeutics
- Target Recruit Count
- 270
- Registration Number
- NCT01736735
- Locations
- 🇺🇸
Orange Country Research Center, Tustin, California, United States
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Sorbent Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT01598740
- Locations
- 🇺🇸
Orange Country Research Center, Tustin, California, United States
Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Sorbent Therapeutics
- Target Recruit Count
- 113
- Registration Number
- NCT01265524
News
Courage Therapeutics Appoints Giovanni Ferrara as CEO to Advance Melanocortin-Targeted Obesity Treatments
Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.